BRCA1 and breast carcinoma: An ongoing phase 1/2 study of olaparib and the PD-L1 inhibitor durvalumab in breast cancer patients with BRCA1/2 mutations demonstrated that 24 of 30 patients who were eligible for trial entry by study design achieved durable and adaptable cancer control at 12 weeks of combination therapy (60).